期刊文献+

奥氮平对体重、肝功能、血糖、血胆固醇水平的影响 被引量:24

The effects of olanzapine on body weight, liver functions, blood sugar and cholesterol level
下载PDF
导出
摘要 目的:回顾性调查奥氮平对患者体重、肝功能、血糖、血胆固醇水平的影响。方法:87例奥氮平治疗至少6周的精神分裂症患者,比较治疗前后体重、谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(T-Bil)、血糖(GLU)、血胆固醇(CHO)的变化。结果:治疗6周后患者体重明显增加,平均增加2.2kg,与基线相比具有显著性差异(P<0.001)。治疗后ALT,AST和CHO水平也明显高于基线值,具有显著性差异(P<0.01)。但治疗后T-Bil水平降低,与基线相比差异具有显著性(P=0.026)。治疗前后血糖无显著差异(P=0.882)。体重的变化与年龄和基线体重呈负相关,相关系数分别为-0.33和-0.32(P=0.003和0.004)。ALT及AST的变化与治疗6周后的体重变化呈正相关,相关系数分别为0.34和0.40(P=0.024和0.007)。结论:奥氮平引起患者体重增加、无症状性转氨酶升高和CHO升高。 Objective:To investigate retrospectively the effects of olanzapine on body weight, liver functions,blood sugar and cholesterol level. Methods:87 patients with schizophrenia have been received olanzapine treatment for at least 6 weeks. The pre- and post-treatment data on their body weight,liver functions,blood sugar and cholesterol levels were compared. Results: Their body weights were obviously increased after treatment, with an average increase of 2. 2kg, and there were significant difference in comparison with baseline data. In comparison with baseline data,their post-treatment data on ALT,AST and CHO (blood cholesterol) were significantly increased (P<0.01) but T-Bil (total bilirubin) was significantly decreased (P = 0. 026) and no GLU level change was observed. Conclusion : The 6 weeks treatment of olanzapine affected the body weight, liver functions and blood cholesterol level of the patients.
出处 《中国新药杂志》 CAS CSCD 北大核心 2003年第10期847-849,共3页 Chinese Journal of New Drugs
关键词 奥氮平 体重 肝功能 血糖 血胆固醇 olanzapine body weight liver function blood glucose blood cholesterol
  • 相关文献

参考文献8

  • 1吴彩云,吴爱勤,李华杰,赵海园.奥氮平治疗精神病性障碍36例初步观察[J].上海精神医学,2000,12(1):45-46. 被引量:48
  • 2郭俊花,翁永振,周方,候也之,陈健生.奥氮平治疗精神分裂症33例临床分析[J].上海精神医学,2000,12(1):46-48. 被引量:17
  • 3郑洪波,邓河晃,周亮.奥氮平维持治疗精神分裂症23例临床评价[J].上海精神医学,2000,12(1):43-44. 被引量:7
  • 4Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol : acute phase results of the North American doubleblind olanzapine trial [ J ]. Neuropsychopharmacology, 1996, 14(2) :111 - 123.
  • 5Green B. Focus on olanzapine[J]. Curr Med Res Opin, 1999,15(2) :79- 85.
  • 6Wirshing DA, Whirshing WC, Kusar L, et al. Novel antipsychotics: Comparison of weight gain liabilities[J ]. J Clin Psychiatry, 1999,60(6) : 358 - 363.
  • 7Wirshing DA,Spellberg BJ ,Erhart SM, et al. Novel antipsychotics and new onset diabetes[J]. Biol Psychiatry, 1998,44(8) : 778 -783.
  • 8Osser DN, Najarian DM, Dufresne RL, et al. Olartzapine increase weight and serum triglyceride levels[J]. J Clin Psychiatry, 1999,60( 11 ) : 767 - 770.

二级参考文献11

  • 1[1]Tran P V,Beasley C,Tollefson G,et al.Acute and long-term results of the close ranging double-blind Olanzapine trial[poster].20th Congress of the International College of Neuropsychopharmacology (CINP),1996 Jun 23~ 27,Melbourne,Australia
  • 2[2]Tran P V,Beasley C,Street J,et al.Olanzapine versus haloperidol:acute results of the multi-center international trial[poster].20th Congress of the International College of Neuropsychopharmacology (CINP),1996 Jun 23~ 27,Melbourne,Australia
  • 3[3]Beasley C M Jr,Tollefson G,Tran P V.Olanzapine versus placebo and haloperidol:acute phase results of the North American doubleblind olanzapine trial.Neuropsychopharmacology,1996,14 (2):111
  • 4[4]Tollefson G D,Beasley C M Jr,Tran P V,et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders:results of an intenational collaborative trial.Am J Psychiatry,1997,154:457~465
  • 5[5]Tollefson G D,Beasley C M Jr,Tanura R N,et al.Blind,controlled,long-term study of the comparative incidence of treatmentemergent tardive dyskinesia with olanzapine or haloperidol.Am J Psychiatry,1997,154:1248~1254
  • 6[1]Beasley C M,Tollefson G D,Tran P V.Efficacy of Olanzapine:An overview of pivotal clinical trials.J Clin Psychiatry,1997,58(suppl 10):7
  • 7[2]Meltzer H Y,Fibiger H C.Olanzapine:a new atypical antipsychotic drug.Neuropsychophamacology,1996,14(2):83~85
  • 8[1]Beasley C M Jr,Tollefson G D,Tran P V.Efficacy of olanzapine:an overview of pivotal trials.J Clin Psychiatry,1997,58 (Suppl 10):7~12
  • 9[2]Beasley C M Jr,Hamilton S H,Crawford A M,et al.Olanzapine versus haloperidol:acute phase results of the international doubleblind olanzapine trial.Eur Neuropsychopharmacology,1997,7:125~137
  • 10[3]Tollefson G D,Beasley C M Jr,Tran P V,et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaaffective and schizophreniform disorder:results of an international collaborative trial.Am J Psychiatry,1997,154:457~465

共引文献57

同被引文献260

引证文献24

二级引证文献216

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部